Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
Purpose. Glioblastoma multiforme (GBM) is optimally treated by maximal debulking followed by combined chemoradiation. Intensity modulated radiation therapy (IMRT) is gaining widespread acceptance in other tumour sites, although evidence to support its use over three-dimensional conformal radiation t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Neurology Research International |
| Online Access: | http://dx.doi.org/10.1155/2014/945620 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563763402768384 |
|---|---|
| author | Noel J. Aherne Linus C. Benjamin Patrick J. Horsley Thomaz Silva Shea Wilcox Julan Amalaseelan Patrick Dwyer Abdul M. R. Tahir Jacques Hill Andrew Last Carmen Hansen Craig S. McLachlan Yvonne L. Lee Michael J. McKay Thomas P. Shakespeare |
| author_facet | Noel J. Aherne Linus C. Benjamin Patrick J. Horsley Thomaz Silva Shea Wilcox Julan Amalaseelan Patrick Dwyer Abdul M. R. Tahir Jacques Hill Andrew Last Carmen Hansen Craig S. McLachlan Yvonne L. Lee Michael J. McKay Thomas P. Shakespeare |
| author_sort | Noel J. Aherne |
| collection | DOAJ |
| description | Purpose. Glioblastoma multiforme (GBM) is optimally treated by maximal debulking followed by combined chemoradiation. Intensity modulated radiation therapy (IMRT) is gaining widespread acceptance in other tumour sites, although evidence to support its use over three-dimensional conformal radiation therapy (3DCRT) in the treatment of gliomas is currently lacking. We examined the survival outcomes for patients with GBM treated with IMRT and Temozolomide. Methods and Materials. In all, 31 patients with GBM were treated with IMRT and 23 of these received chemoradiation with Temozolomide. We correlated survival outcomes with patient functional status, extent of surgery, radiation dose, and use of chemotherapy. Results. Median survival for all patients was 11.3 months, with a median survival of 7.2 months for patients receiving 40.05 Gray (Gy) and a median survival of 17.4 months for patients receiving 60 Gy. Conclusions. We report one of the few series of IMRT in patients with GBM. In our group, median survival for those receiving 60 Gy with Temozolomide compared favourably to the combined therapy arm of the largest randomised trial of chemoradiation versus radiation to date (17.4 months versus 14.6 months). We propose that IMRT should be considered as an alternative to 3DCRT for patients with GBM. |
| format | Article |
| id | doaj-art-39c779dc1998492199ef0827de7a97e2 |
| institution | Kabale University |
| issn | 2090-1852 2090-1860 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neurology Research International |
| spelling | doaj-art-39c779dc1998492199ef0827de7a97e22025-02-03T01:12:35ZengWileyNeurology Research International2090-18522090-18602014-01-01201410.1155/2014/945620945620Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma MultiformeNoel J. Aherne0Linus C. Benjamin1Patrick J. Horsley2Thomaz Silva3Shea Wilcox4Julan Amalaseelan5Patrick Dwyer6Abdul M. R. Tahir7Jacques Hill8Andrew Last9Carmen Hansen10Craig S. McLachlan11Yvonne L. Lee12Michael J. McKay13Thomas P. Shakespeare14Department of Radiation Oncology, North Coast Cancer Institute, Coffs Harbour, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Coffs Harbour, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Coffs Harbour, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Lismore, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Port Macquarie, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Lismore, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Lismore, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Coffs Harbour, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Port Macquarie, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Port Macquarie, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Port Macquarie, NSW, AustraliaRural Clinical School Faculty of Medicine, University of New South Wales, NSW, AustraliaRural Clinical School Faculty of Medicine, University of New South Wales, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Lismore, NSW, AustraliaDepartment of Radiation Oncology, North Coast Cancer Institute, Coffs Harbour, NSW, AustraliaPurpose. Glioblastoma multiforme (GBM) is optimally treated by maximal debulking followed by combined chemoradiation. Intensity modulated radiation therapy (IMRT) is gaining widespread acceptance in other tumour sites, although evidence to support its use over three-dimensional conformal radiation therapy (3DCRT) in the treatment of gliomas is currently lacking. We examined the survival outcomes for patients with GBM treated with IMRT and Temozolomide. Methods and Materials. In all, 31 patients with GBM were treated with IMRT and 23 of these received chemoradiation with Temozolomide. We correlated survival outcomes with patient functional status, extent of surgery, radiation dose, and use of chemotherapy. Results. Median survival for all patients was 11.3 months, with a median survival of 7.2 months for patients receiving 40.05 Gray (Gy) and a median survival of 17.4 months for patients receiving 60 Gy. Conclusions. We report one of the few series of IMRT in patients with GBM. In our group, median survival for those receiving 60 Gy with Temozolomide compared favourably to the combined therapy arm of the largest randomised trial of chemoradiation versus radiation to date (17.4 months versus 14.6 months). We propose that IMRT should be considered as an alternative to 3DCRT for patients with GBM.http://dx.doi.org/10.1155/2014/945620 |
| spellingShingle | Noel J. Aherne Linus C. Benjamin Patrick J. Horsley Thomaz Silva Shea Wilcox Julan Amalaseelan Patrick Dwyer Abdul M. R. Tahir Jacques Hill Andrew Last Carmen Hansen Craig S. McLachlan Yvonne L. Lee Michael J. McKay Thomas P. Shakespeare Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme Neurology Research International |
| title | Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme |
| title_full | Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme |
| title_fullStr | Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme |
| title_full_unstemmed | Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme |
| title_short | Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme |
| title_sort | improved outcomes with intensity modulated radiation therapy combined with temozolomide for newly diagnosed glioblastoma multiforme |
| url | http://dx.doi.org/10.1155/2014/945620 |
| work_keys_str_mv | AT noeljaherne improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT linuscbenjamin improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT patrickjhorsley improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT thomazsilva improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT sheawilcox improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT julanamalaseelan improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT patrickdwyer improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT abdulmrtahir improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT jacqueshill improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT andrewlast improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT carmenhansen improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT craigsmclachlan improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT yvonnellee improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT michaeljmckay improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme AT thomaspshakespeare improvedoutcomeswithintensitymodulatedradiationtherapycombinedwithtemozolomidefornewlydiagnosedglioblastomamultiforme |